Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
1.00
-0.09 (-8.26%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.99 - 1.12
52 week 0.84 - 3.84
Open 1.09
Vol / Avg. 817,018.00/387,547.00
Mkt cap 46.50M
P/E     -
Div/yield     -
EPS -1.39
Shares 50.69M
Beta 2.60
Inst. own 72%
Nov 7, 2017
Q3 2017 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 3, 2017
Q2 2017 Infinity Pharmaceuticals Inc Earnings Call
Aug 3, 2017
Q2 2017 Infinity Pharmaceuticals Inc Earnings Release
Jun 22, 2017
Infinity Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) International Convention
Jun 21, 2017
Infinity Pharmaceuticals Inc at JMP Securities Life Science Conference - "Immuno-Oncology: Novel Approaches" Panel
May 25, 2017
Infinity Pharmaceuticals Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -160.77%
Operating margin - -164.99%
EBITD margin - -746.08%
Return on average assets -69.94% -14.52%
Return on average equity -102.50% -33.26%
Employees 23 -
CDP Score - -

Address

784 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Officers and directors

Adelene Q. Perkins Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D. J.D. President, Principal Financial Officer, Principal Accounting Officer
Age: 52
Bio & Compensation  - Reuters
William C. Bertrand Jr. Esq. Executive Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Melissa Hackel Vice President - Finance
Bio & Compensation  - Reuters
Joseph Pearlberg M.D. Ph.D. Vice President - Clinical Development
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Michael G. Kauffman M.D., Ph.D. Independent Director
Bio & Compensation  - Reuters
Ian F. Smith CPA Independent Director
Age: 51
Bio & Compensation  - Reuters